Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung Cancer

Cytology and histology forms the cornerstone for the diagnosis of non-small cell lung cancer (NSCLC) but obtaining sufficient tumour cells or tissue biopsies for these tests remains a challenge. We investigate the lipidome of lung pleural effusion (PE) for unique metabolic signatures to discriminate benign versus malignant PE and EGFR versus non-EGFR malignant subgroups to identify novel diagnostic markers that is independent of tumour cell availability. Using liquid chromatography mass spectrometry, we profiled the lipidomes of the PE of 30 benign and 41 malignant cases with or without EGFR mutation. Unsupervised principal component analysis revealed distinctive differences between the lipidomes of benign and malignant PE as well as between EGFR mutants and non-EGFR mutants. Docosapentaenoic acid and Docosahexaenoic acid gave superior sensitivity and specificity for detecting NSCLC when used singly. Additionally, several 20- and 22- carbon polyunsaturated fatty acids and phospholipid species were significantly elevated in the EGFR mutants compared to non-EGFR mutants. A 7-lipid panel showed great promise in the stratification of EGFR from non-EGFR malignant PE. Our data revealed novel lipid candidate markers in the non-cellular fraction of PE that holds potential to aid the diagnosis of benign, EGFR mutation positive and negative NSCLC.

[1]  F. Snyder,et al.  Alkyl and alk-1-enyl ethers of glycerol in lipids from normal and neoplastic human tissues. , 1969, Cancer research.

[2]  Jason Weston,et al.  Gene Selection for Cancer Classification using Support Vector Machines , 2002, Machine Learning.

[3]  D. Ray,et al.  The role of the liver X receptor in chronic obstructive pulmonary disease , 2013, Respiratory Research.

[4]  E. V. Dyatlovitskaya,et al.  Role of biologically active sphingolipids in tumor growth , 2006, Biochemistry (Moscow).

[5]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[6]  S. Beloribi-Djefaflia,et al.  Lipid metabolic reprogramming in cancer cells , 2016, Oncogenesis.

[7]  D. Mangelsdorf,et al.  Role of LXRs in control of lipogenesis. , 2000, Genes & development.

[8]  Chih-Jen Lin,et al.  LIBSVM: A library for support vector machines , 2011, TIST.

[9]  C. Thompson,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[10]  L. Burgess.  Biochemical analysis of pleural, peritoneal and pericardial effusions. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[11]  P. Escribá,et al.  Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy , 2011, Proceedings of the National Academy of Sciences.

[12]  A. Nicholson,et al.  Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. , 2013, Archives of pathology & laboratory medicine.

[13]  S. Horvath,et al.  EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy , 2009, Science Signaling.

[14]  A. Giuliano,et al.  Ceramide glycosylation potentiates cellular multidrug resistance , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  Jasper Snoek,et al.  Practical Bayesian Optimization of Machine Learning Algorithms , 2012, NIPS.

[16]  Yu-hao Zhou,et al.  Effect of omega-3 fatty acid supplementation on cancer incidence, non-vascular death, and total mortality: a meta-analysis of randomized controlled trials , 2014, BMC Public Health.

[17]  C. Field,et al.  (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. , 2007, The Journal of nutrition.

[18]  E. Gulbins,et al.  Ceramide-enriched membrane domains. , 2005, Biochimica et biophysica acta.

[19]  S. Limborska,et al.  Expression of sphingomyelin synthase 1 (SGMS1) gene varies in human lung and esophagus cancer , 2014, Molecular Biology.

[20]  N. Nagan,et al.  Plasmalogens: biosynthesis and functions. , 2001, Progress in lipid research.

[21]  M. Pratter,et al.  A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. , 2008, Chest.

[22]  J. G. García Díaz,et al.  Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. , 2008, Anticancer research.

[23]  Suzanne E Dahlberg,et al.  Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. , 2016, JAMA oncology.

[24]  E. Gulbins,et al.  Biological aspects of ceramide-enriched membrane domains. , 2007, Progress in lipid research.

[25]  R. Mancini,et al.  Stearoyl-CoA desaturase-1 is a key factor for lung cancer-initiating cells , 2013, Cell Death and Disease.

[26]  A. A. Obrer,et al.  La toracocentesis en la evaluación del cáncer de pulmón con derrame pleural , 2002 .

[27]  H. Sone,et al.  Polyunsaturated Fatty Acids Suppress Sterol Regulatory Element-binding Protein 1c Promoter Activity by Inhibition of Liver X Receptor (LXR) Binding to LXR Response Elements* , 2002, The Journal of Biological Chemistry.

[28]  Melinda M. Mulvihill,et al.  Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity , 2013, Proceedings of the National Academy of Sciences.

[29]  C. Jun,et al.  Performance of some variable selection methods when multicollinearity is present , 2005 .

[30]  G. J. Yoshida.  Metabolic reprogramming: the emerging concept and associated therapeutic strategies , 2015, Journal of Experimental & Clinical Cancer Research.

[31]  Chih-Pin Chuu,et al.  Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines. , 2010, Anticancer research.

[32]  P. Edwards,et al.  LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition. , 2013, Cell metabolism.

[33]  P. Tontonoz,et al.  Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR , 2012, Nature Reviews Molecular Cell Biology.

[34]  A. Giuliano,et al.  Glucosylceramide: a marker for multiple-drug resistant cancers. , 1998, Anticancer research.

[35]  M. Gavish,et al.  Pleural fluid analysis of lung cancer vs benign inflammatory disease patients , 2010, British Journal of Cancer.

[36]  R. McCormack,et al.  The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies , 2013, Journal of Clinical Pathology.

[37]  M. Chua,et al.  The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: A meta-analysis. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[38]  W. Demark-Wahnefried,et al.  Current Evidence Linking Polyunsaturated Fatty Acids with Cancer Risk and Progression , 2013, Front. Oncol..

[39]  Joshua D. Knowles,et al.  Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry , 2011, Nature Protocols.

[40]  G. Homanics,et al.  Activation of the Liver X Receptor Prevents Lipopolysaccharide-induced Lung Injury* , 2009, The Journal of Biological Chemistry.

[41]  R. Kolesnick,et al.  Raft ceramide in molecular medicine , 2003, Oncogene.

[42]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[43]  Steven E Schild,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[44]  Jian-Xin Li,et al.  Metabonomic classification and detection of small molecule biomarkers of malignant pleural effusions , 2012, Analytical and Bioanalytical Chemistry.

[45]  M. Wahidi,et al.  Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[46]  C. Lam,et al.  Untargeted mass spectrometry-based metabolomic profiling of pleural effusions: fatty acids as novel cancer biomarkers for malignant pleural effusions. , 2014, Journal of proteome research.

[47]  Peter Tontonoz,et al.  Liver X receptors in lipid metabolism: opportunities for drug discovery , 2014, Nature Reviews Drug Discovery.

[48]  H. Kleinman,et al.  Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. , 2002, Cancer research.

[49]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[50]  M. Touvier,et al.  Prospective Associations between Plasma Saturated, Monounsaturated and Polyunsaturated Fatty Acids and Overall and Breast Cancer Risk – Modulation by Antioxidants: A Nested Case-Control Study , 2014, PloS one.

[51]  M. Ciccozzi,et al.  Analysis of the ORFK1 hypervariable regions reveal distinct HHV-8 clustering in Kaposi’s sarcoma and non-Kaposi’s cases , 2015, Journal of experimental & clinical cancer research : CR.

[52]  R. Abagyan,et al.  XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. , 2006, Analytical chemistry.

[53]  T. Goldkorn,et al.  Lung cancer and lung injury: the dual role of ceramide. , 2013, Handbook of experimental pharmacology.

[54]  F. Askin,et al.  Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[55]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[56]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[57]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[58]  P. Mischel,et al.  Targeting SREBP-1-driven lipid metabolism to treat cancer. , 2014, Current pharmaceutical design.

[59]  R. Tibshirani,et al.  Improvements on Cross-Validation: The 632+ Bootstrap Method , 1997 .

[60]  T. Ravid,et al.  EGF Receptor Exposed to Oxidative Stress Acquires Abnormal Phosphorylation and Aberrant Activated Conformation That Impairs Canonical Dimerization , 2011, PloS one.

[61]  M. Ibarguren,et al.  Cholesterol displacement by ceramide in sphingomyelin‐containing liquid‐ordered domains, and generation of gel regions in giant lipidic vesicles , 2008, FEBS letters.

[62]  D. Ma,et al.  The Role of n-3 Polyunsaturated Fatty Acids in the Prevention and Treatment of Breast Cancer , 2014, Nutrients.

[63]  E. Felip,et al.  Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. , 2015, JAMA oncology.

[64]  Karin Dahlman-Wright,et al.  Liver X receptor in cholesterol metabolism. , 2010, Journal of Endocrinology.

[65]  T. Tsuruo,et al.  De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy , 2009, British Journal of Cancer.

[66]  J. Remon,et al.  Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. , 2013, Translational lung cancer research.

[67]  A. Borczuk,et al.  Epidermal growth factor receptor mutations in lung adenocarcinoma , 2014, Laboratory Investigation.

[68]  H. Sampath,et al.  Polyunsaturated fatty acid regulation of genes of lipid metabolism. , 2005, Annual review of nutrition.

[69]  Xiaojun Tang,et al.  A community-based approach to non-communicable chronic disease management within a context of advancing universal health coverage in China: progress and challenges , 2014, BMC Public Health.

[70]  Alfred Böcking,et al.  Diagnostic accuracy of effusion cytology , 1999, Diagnostic cytopathology.

[71]  J. M. Porcel,et al.  Diagnostic approach to pleural effusion in adults. , 2006, American family physician.

[72]  J. Fargnoli,et al.  Cancer Cell Dependence on Unsaturated Fatty Acids Implicates Stearoyl-CoA Desaturase as a Target for Cancer Therapy , 2011, Molecular Cancer Research.

[73]  A. Nègre-Salvayre,et al.  Activation of epithelial growth factor receptor pathway by unsaturated fatty acids. , 1999, Circulation research.

[74]  S. Bielsa,et al.  Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. , 2009, American journal of respiratory and critical care medicine.

[75]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[76]  H. Dienemann,et al.  Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles , 2015, International journal of cancer.

[77]  J. Gustafsson,et al.  Ablation of Liver X receptors α and β leads to spontaneous peripheral squamous cell lung cancer in mice , 2016, Proceedings of the National Academy of Sciences.

[78]  H. Cao,et al.  LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation. , 2015, Biochemical and biophysical research communications.